= INFORMATION HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT ARCUS BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT NO. 4 TO LICENSE AGREEMENTLicense Agreement • February 28th, 2023 • Arcus Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 28th, 2023 Company IndustryThis AMENDMENT NO. 4 (the “Amendment”) is made and entered into as of December 30, 2022 (“Effective Date”), by and between Arcus Biosciences, Inc. (“Arcus”), with offices at 3928 Point Eden Way, Hayward, CA 94545, U.S.A., and WuXi Biologics Ireland Limited (successor-in-interest to WuXi Biologics (Cayman) Inc., “WuXi”), with an address at One Spencer Dock, North Wall Quay, Dublin 1, Ireland. Arcus and WuXi may be referred to in this Amendment individually as a “Party” or together as the “Parties.”